On May 5, 2026 Alloy Therapeutics, a leading biotechnology ecosystem company, reported a strategic collaboration with the Institute for Protein Innovation (IPI), a nonprofit leader in protein engineering and in vitro discovery. Together, the organizations will create bespoke VHH (nanobody) libraries designed to power next-generation antibody discovery, including bispecific and multispecific therapeutics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration combines Alloy’s integrated drug discovery and development infrastructure and scalable platform ecosystem with IPI’s world-renowned expertise in synthetic antibody discovery, high-throughput in vitro platforms, and advanced protein engineering. The result is a new class of highly engineered, humanized VHH libraries optimized for developability, translational potential, and broad accessibility across the biotech and pharmaceutical landscape.

Through this partnership, Alloy and IPI aim to make advanced discovery tools more widely available, enabling researchers and drug developers to move faster while tackling increasingly complex biological targets, particularly in areas like neuroscience, where traditional antibody approaches often fall short.

"This collaboration reflects the pace at which innovation is happening in our industry and the need to bring the best technologies together under one ecosystem," said Errik Anderson, CEO and Founder of Alloy Therapeutics. "By integrating IPI’s cutting-edge in vitro discovery and protein engineering capabilities with Alloy’s in vivo capabilities, we are expanding what’s possible in antibody design, especially for multispecific formats, while maintaining the speed and scalability that today’s drug developers demand."

As part of the collaboration, IPI has developed two synthetic, humanized VHH libraries using yeast display, incorporating advanced protein engineering principles to improve stability, reduce immunogenicity, and enhance overall developability. The libraries are designed with plug-and-play functionality, enabling seamless integration into a variety of therapeutic formats, including bispecific and multispecific constructs.

IPI’s approach emphasizes real-world application and iteration, working closely with partners to refine technologies based on the evolving needs of drug developers. The organization’s mission-driven focus on open science and broad access ensures that these innovations can benefit both industry and academic communities.

"We recognize the need for protein tools that enhance biological investigations in both commercial and academic settings and industry’s demand for platforms that accelerate therapeutic discovery," said Ken Fasman, President and CEO of IPI. "As a nonprofit with industrial-scale capabilities, our Institute is uniquely positioned to collaborate with partners like Alloy—meeting their needs and advancing the broader drug development ecosystem."

VHH antibodies are emerging as a critical component of next-generation therapeutics due to their small size, stability, and ability to access challenging targets. Their modularity also makes them uniquely suited for building complex multispecific molecules, a key strategic focus for Alloy as it continues to expand its technical stack and AI-driven discovery capabilities.

By combining IPI’s technology with Alloy’s integrated discovery program, the collaboration creates a powerful engine for innovation. Biotech and pharma partners will be able to leverage these capabilities to outsource hit discovery, accelerate development timelines, and increase their probability of success.

The joint effort underscores both organizations’ commitment to advancing protein science, enabling broader access to cutting-edge tools, and ultimately improving human health through faster, more effective therapeutic discovery.

(Press release, Alloy Therapeutics, MAY 5, 2026, View Source [SID1234665103])

On May 5, 2026 Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, reported that management will be participating in fireside chats at the following upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bank of America Securities Health Care Conference
Date: Tuesday, May 12, 2026
Fireside Chat Time: 3:40 p.m. PT
Location: Las Vegas

RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 20, 2026
Fireside Chat Time: 2:35 p.m. ET
Location: New York

Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Fireside Chat Time: 4:55 p.m. ET
Location: New York

The fireside chats will be webcast live. To join the webcasts, please visit the Events and Presentations page of the Investors & Media section on Intellia’s website at intelliatx.com. Replays of the webcasts will be available on the same page for approximately 90 days following the events.

(Press release, Intellia, MAY 5, 2026, View Source [SID1234665120])

On May 5, 2026 Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, reported first quarter 2026 financial results and corporate updates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have made important progress so far in 2026, highlighted by promising data supporting further development for the zovegalisib plus atirmociclib triplet combination in frontline breast cancer," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. "With initial clinical data in vascular anomalies expected at ISSVA and preparations underway for our planned Phase 3 frontline study in endocrine-sensitive patients with metastatic breast cancer, we are entering a data-rich period for zovegalisib. Additionally, RLY-8161, our NRAS-selective molecule, has entered clinical development for patients with NRAS-mutant solid tumors. We remain focused on executing across these priorities to bring differentiated therapies to patients."

Corporate Highlights

2L Breast Cancer

•
U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to zovegalisib in combination with fulvestrant for PIK3CA-mutant, HR+/HER2- advanced breast cancer
o
Designation supported by robust clinical data from the Phase 1/2 ReDiscover trial of 600mg twice daily (BID) fasted and 400mg BID fed regimens of zovegalisib in combination with fulvestrant
•
Presented 400mg BID zovegalisib doublet data at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Targeted Anticancer Therapies (TAT) Congress 2026

o
11.1-month median progression-free survival (PFS) observed in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, consistent with previously reported data
o
Efficacy in patients with kinase and non-kinase domain mutations was similar, with median PFS of 11.2 and 11.0 months, respectively
o
Safety and tolerability data were consistent with previously reported 600mg BID fasted data
•
Relay Tx continues to execute on the Phase 3 ReDiscover-2 trial of zovegalisib + fulvestrant in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- advanced breast cancer
1L Breast Cancer

•
Announced clinical data for zovegalisib plus atirmociclib triplet combination, plans for frontline breast cancer study, and clinical supply agreement with Pfizer
o
Compelling efficacy and tolerability data presented for zovegalisib triplet in median third-line (3L) patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
o
44% objective response rate (ORR) reported in heavily pre-treated CDK4/6-experienced patients (median 3L) at unoptimized doses and ORR was similar across kinase and non-kinase PIK3CA mutations
o
Adverse events were consistent with those previously reported by each molecule
o
Phase 3 1L trial in patients with endocrine-sensitive breast cancer expected to initiate in early 2027, subject to regulatory feedback
▪
Pfizer has agreed to supply atirmociclib for the experimental arm and the palbociclib portion of the control arm for use in the planned study, and Relay Tx will retain full global rights for zovegalisib
•
Relay Tx continues to execute the Phase 1/2 ReDiscover trial, advancing the ongoing triplet cohorts with zovegalisib + atirmociclib + endocrine therapy
Vascular Anomalies

•
Corporate conference call planned for May 19 at 8:00am ET during the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026 to announce initial clinical results for zovegalisib in vascular anomalies
o
Late breaking abstract for clinical data to be presented May 20 from 4:45pm-4:49pm ET
o
Pre-clinical data presentation May 22 at 11:10am ET
o
Conference call details to be shared at a later date
•
Continued execution of the Phase 1/2 ReInspire trial, evaluating zovegalisib in PIK3CA-driven vascular anomalies
NRAS Selective Inhibitor: RLY-8161

•
Initiated Phase 1/2 clinical trial for RLY-8161, a NRAS-selective inhibitor, in patients with NRAS-mutant melanoma and other NRAS-mutant solid tumors

First Quarter 2026 Financial Results

Cash, Cash Equivalents and Investments: As of March 31, 2026, cash, cash equivalents and investments totaled $642.1 million, as compared to $554.5 million as of December 31, 2025. The increase in cash was due to $137.1 million in net proceeds from "at-the-market" offerings under our sales agreement with TD Securities (USA) LLC during the quarter. This figure does not include an additional $22.1 million in net proceeds received from "at-the-market" offerings in April. The company expects its current cash, cash equivalents, and investments will be sufficient to fund its operating expenses and capital expenditure requirements into 2029.

Revenue: Revenue was $3.0 million for the first quarter of 2026, as compared to $7.7 million for the first quarter of 2025. The revenue recognized in each period was under the company’s Exclusive License Agreement with Elevar Therapeutics, Inc.

R&D Expenses: Research and development expenses were $70.6 million for the first quarter of 2026, as compared to $73.8 million for the first quarter of 2025. The decrease was primarily due to the series of strategic choices made to streamline the research organization prior to 2026, offset by increases in costs related to the ReDiscover-2 trial.

G&A Expenses: General and administrative expenses were $11.0 million for the first quarter of 2026, as compared to $18.7 million for the first quarter of 2025. The decrease was primarily due to decreases in employee compensation costs, including stock compensation expense, and costs to obtain the Exclusive License Agreement with Elevar Therapeutics, Inc., which were expensed during the three months ended March 31, 2025.

Net Loss: Net loss was $73.3 million for the first quarter of 2026, or a net loss per share of $0.41, as compared to a net loss of $77.1 million for the first quarter of 2025, or a net loss per share of $0.46.

About Zovegalisib

Zovegalisib is the lead program in Relay Therapeutics’ efforts to discover and develop mutant-selective inhibitors of PI3Kα, the most frequently mutated kinase in all cancers and all vascular anomalies. Zovegalisib has the potential, if approved, to address a significant portion of the approximately 140,000 patients with HR+/HER2- breast cancer with a PI3Kα mutation and the estimated 170,000 patients with vascular anomalies driven by a PI3Kα mutation per year in the United States, one of the largest patient populations for a precision medicine.

Traditionally, the development of PI3Kα inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3Kα and off-isoform activity. Toxicity related to inhibition of WT PI3Kα and other PI3K isoforms results in sub-optimal inhibition of mutant PI3Kα with reductions in dose intensity and frequent discontinuation. The Dynamo platform enabled the discovery of zovegalisib, the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3Kα, performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3Kα, and leveraged these insights to support the design of zovegalisib. Zovegalisib is currently being evaluated in multiple metastatic breast cancer studies and a Phase 1/2 study designed to treat patients with PIK3CA (PI3Kα) mutation driven vascular anomalies.

(Press release, Relay Therapeutics, MAY 5, 2026, View Source [SID1234665140])

On May 5, 2026 Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, reported that members of the management team are scheduled to present at the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bank of America Securities 2026 Healthcare Conference
Presentation on Tuesday, May 12 at 4:35 p.m. ET in Las Vegas, NV

2026 Stifel Virtual Targeted Oncology Forum
Virtual presentation on Wednesday, May 20 at 12:00 p.m. ET

A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.

(Press release, Geron, MAY 5, 2026, View Source [SID1234665155])

On May 5, 2026 Applied Cells reported a collaboration with SHENTEK to integrate fast QC release solution with Applied Cells’ GoFast CAR-T manufacturing workflow on the MARS platforms.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GoFast CAR-T is Applied Cells’ advanced rapid CAR-T manufacturing workflow designed to support closed-fluidic CAR-T production in less than 72 hours. Built on the MARS platforms, the workflow simplifies key steps including immunomagnetic T cell isolation, activation and transduction, wash, concentration, and media exchange in a streamlined process. GoFast workflow is designed to help cell therapy teams reduce complexity, accelerate manufacturing timelines, and support more scalable and cost-effective CAR-T production.

Through this collaboration, Applied Cells and SHENTEK will work together to launch Hubble, a qPCR platform with fast QC capabilities that supports same-day QC release testing of cell therapy products.

Hubble provides a hands-free approach by combining nucleic acid extraction and real-time PCR into a fully integrated, automated single-use cartridge solution. This system is designed to deliver results from sample-to-result in less than 3 hours, and offers walk-away operation. The platform features integrated internal controls, 21 CFR Part 11 compliance, and broad detection coverage for more than 180 species of Mycoplasma, Spiroplasma, and Acholeplasma currently, with sterility, VCN, and RCL capabilities planned for the near future.

"Fast, reliable QC is essential to making rapid CAR-T manufacturing more accessible," said Yuchen Zhou, CEO of Applied Cells. "By collaborating with SHENTEK, we are providing the cell therapy industry a more complete, even faster, and further lower-cost solution. Together, we aim to help cell therapies move closer to affordability, and scalable production."

This collaboration is part of Applied Cells’ broader mission to enable low cost, fast, simple, and scalable cell therapy manufacturing for global users. By pairing the MARS GoFast workflow with Hubble, Applied Cells and SHENTEK aim to accelerate patient access of life-saving CAR-T cell therapies around the world.

Applied Cells and SHENTEK will showcase the GoFast CAR-T workflow and Hubble Fast QC capabilities together at ASGCT (Free ASGCT Whitepaper) 2026. Attendees can visit Poster #2398 for GoFast CAR-T, Poster #1197 for Hubble Fast QC, and Booth #932 to learn more about the collaboration and early access opportunities.

(Press release, Applied Cells, MAY 5, 2026, View Source [SID1234665104])